131 related articles for article (PubMed ID: 10160075)
1. The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden.
Unge P; Jönsson B; Stålhammar NO
Pharmacoeconomics; 1995 Nov; 8(5):410-27. PubMed ID: 10160075
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease.
Jönsson B
Scand J Gastroenterol Suppl; 1996; 215():90-5. PubMed ID: 8722390
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of H. pylori eradication.
Roesch W
J Physiol Pharmacol; 1996 Mar; 47(1):71-7. PubMed ID: 8777309
[No Abstract] [Full Text] [Related]
4. Helicobacter pylori eradication in duodenal ulcer disease is cost-beneficial: a Belgian model.
Deltenre M; Ilunga KO
J Physiol Pharmacol; 1997 Sep; 48 Suppl 4():107-13. PubMed ID: 9440061
[TBL] [Abstract][Full Text] [Related]
5. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin.
Craig AM; Davey P; Malek M; Murray F
Pharmacoeconomics; 1996 Jul; 10(1):79-92. PubMed ID: 10160472
[TBL] [Abstract][Full Text] [Related]
6. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group.
Sonnenberg A; Schwartz JS; Cutler AF; Vakil N; Bloom BS
Arch Intern Med; 1998 Apr; 158(8):852-60. PubMed ID: 9570170
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives.
Tennvall GR; Norinder A; Ohlin B
Pharmacoeconomics; 1999 Sep; 16(3):297-306. PubMed ID: 10558041
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation in gastrointestinal disease.
Jönsson B; Karlsson G
Scand J Gastroenterol Suppl; 1996; 220():44-51. PubMed ID: 8898435
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness analysis of the eradication of Helicobacter pylori as treatment for duodenal ulcer].
Fernández Muñoz J; López de Andrés A; Zapater Hernández P; Abad Santos F
An Med Interna; 1998 Oct; 15(10):515-22. PubMed ID: 9844225
[TBL] [Abstract][Full Text] [Related]
10. Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.
Tavakoli M; Prach AT; Malek M; Hopwood D; Senior BW; Murray FE
Pharmacoeconomics; 1999 Oct; 16(4):355-65. PubMed ID: 10623364
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of Helicobacter pylori eradication for the treatment of duodenal ulcer disease in Japan: a decision analysis to assess eradication strategy in comparison with a conventional strategy.
Habu Y; Inokuchi H; Kiyota K; Hayashi K; Watanabe Y; Kawai K; Stålhammar NO
J Gastroenterol Hepatol; 1998 Mar; 13(3):280-7. PubMed ID: 9570241
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada.
O'Brien B; Goeree R; Mohamed AH; Hunt R
Arch Intern Med; 1995 Oct; 155(18):1958-64. PubMed ID: 7575049
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
Vakil N; Fennerty MB
Am J Gastroenterol; 1996 Feb; 91(2):239-45. PubMed ID: 8607487
[TBL] [Abstract][Full Text] [Related]
14. [Choice of anti-helicobacter treatment of gastroduodenal ulcer associated with helicobater pylori].
Starostin BD
Ter Arkh; 1999; 71(8):46-50. PubMed ID: 10515037
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer.
Sonnenberg A; Pauly MP; Levenson SD; Schwartz JS
Am J Manag Care; 1999 Jan; 5(1):53-9. PubMed ID: 10345967
[TBL] [Abstract][Full Text] [Related]
16. Evolving therapy for Helicobacter pylori infection: efficacy and economic impact in the treatment of patients with duodenal ulcer disease.
Cutler AF; Vakil N
Am J Manag Care; 1997 Oct; 3(10):1528-34. PubMed ID: 10178459
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of different strategies for treating duodenal ulcer. Helicobacter pylori eradication versus antisecretory treatment.
Badia X; Segú JL; Ollé A; Brosa M; Monés J; García Ponte L
Pharmacoeconomics; 1997 Apr; 11(4):367-76. PubMed ID: 10166411
[TBL] [Abstract][Full Text] [Related]
18. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis.
Ford AC; Delaney BC; Forman D; Moayyedi P
Am J Gastroenterol; 2004 Sep; 99(9):1833-55. PubMed ID: 15330927
[TBL] [Abstract][Full Text] [Related]
19. A cost analysis of alternative treatments for duodenal ulcer.
Imperiale TF; Speroff T; Cebul RD; McCullough AJ
Ann Intern Med; 1995 Nov; 123(9):665-72. PubMed ID: 7574221
[TBL] [Abstract][Full Text] [Related]
20. [Medico-economic aspects of the treatment of duodenal ulcer: from antisecretory treatment to eradication of Helicobacter pylori].
Carrère MO; Auquier P; Poynard T; Sambuc R
Gastroenterol Clin Biol; 1995 Dec; 19(12):1023-30. PubMed ID: 8729415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
